Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome

Biochemical and Biophysical Research Communications

Volumn 419, Issue 4, 2012, Pages 662-669

  Iriyama, Chisako ^a   Tomita, Akihiro ^a   Hoshino, Hideaki ^a   Adachi Shirahata, Mizuho ^a   Furukawa Hibi, Yoko ^b   Yamada, Kiyofumi ^b   Kiyoi, Hitoshi ^a   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Circulating DNA; Epigenetics; Genetic mutations; LINE 1; MDS; TET2

Indexed keywords

AZACITIDINE; BISULFITE; CD34 ANTIGEN; CD38 ANTIGEN; CELL DNA; DNA; DNA FRAGMENT;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLAST CELL; BLOOD SAMPLING; BONE MARROW; BONE MARROW CELL; CELL COUNT; CELL FREE SYSTEM; CELL POPULATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; NUCLEOSOME; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SERUM;

AGED; CPG ISLANDS; DNA; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENETIC MARKERS; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84858747507     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.071     Document Type: Article

References (17)

1. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., Fulton R., Schmidt H., Kalicki-Veizer J., O'Laughlin M., Kandoth C., Baty J., Westervelt P., DiPersio J.F., Mardis E.R., Wilson R.K., Ley T.J., Graubert T.A. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25:1153-1158.
2. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
3. Yoshida K., Sanada M., Shiraishi Y., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
4. Kim M., Oh B., Kim S.Y., et al. P15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study. Leuk. Res. 2010, 34:718-722.
5. Lin J., Wang Y.L., Qian J., et al. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome. Leuk. Res. 2010, 34:991-994.
6. Shen L., Kantarjian H., Guo Y., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J. Clin. Oncol. 2010, 28:605-613.
7. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
8. Garcia-Manero G., Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J. Clin. Oncol. 2011, 29:516-523.
9. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
10. Allen D., Butt A., Cahill D., Wheeler M., Popert R., Swaminathan R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann. NY Acad. Sci. 2004, 1022:76-80.
11. Goto E., Tomita A., Hayakawa F., Atsumi A., Kiyoi H., Naoe T. Missense mutations in PML-RARA critical for the lack of responsiveness to arsenic trioxide treatment. Blood 2011, 118:1600-1609.
12. Ohka F., Natsume A., Motomura K., et al. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS ONE 2011, 6:e23332.
13. Sanada M., Suzuki T., Shih L.Y., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460:904-908.
14. Abe A., Minami Y., Hayakawa F., et al. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int. J. Hematol. 2008, 88:471-475.
15. Wolffe A.P. Transcriptional activation. Switched-on chromatin. Curr. Biol. 1994, 4:525-528.
16. Balassiano K., Lima S., Jenab M., et al. Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett. 2011, 311:85-95.
17. Uchida T., Kinoshita T., Nagai H., et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997, 90:1403-1409.